Precision oncology company CelLBxHealth plc (AIM: CLBX) (OTCQX: ANPCY) reported on Wednesday that it has presented proof-of-concept data showing compatibility between its Parsortix circulating tumour cell (CTC) platform and Roche Tissue Diagnostics' BenchMark ULTRA automated staining system at the 16th World ADC Conference in San Diego, held from 3-6 November 2025.

The study validated the combined use of CelLBxHealth's Parsortix platform and proprietary CellKeep slide with Roche's BenchMark ULTRA immunohistochemistry (IHC) platform for biomarker analysis of three key antibody-drug conjugate (ADC) targets - HER2 (breast), TROP2 (lung), and PSMA (prostate). Results confirmed successful processing and automated IHC staining of cancer cell lines using Roche's HER2, TROP2 and PSMA assays, demonstrating full compatibility with CelLBxHealth's manual immunofluorescent workflow.

Integration of CTC-based biomarker testing into ADC development offers a less invasive and more dynamic alternative to traditional tissue biopsies, supporting real-time disease monitoring and patient selection for targeted therapies.

The findings highlight CelLBxHealth's potential to advance precision oncology and ADC development through CTC-based biomarker assessment. The Company's patented Parsortix platform isolates intact tumour cells from blood for detailed downstream analysis and can integrate with standard laboratory systems for imaging, proteomics, and genomics.

CelLBxHealth's precision oncology business is focused on product sales, lab-developed tests and laboratory services from its GCLP-certified UK facility.